Your browser doesn't support javascript.
[Kinetics of SARS-CoV-2-specific antibodies among inactivated COVID-19 vaccine recipients, SARS-CoV-2 natural infection cases, and breakthrough cases].
Jin, L R; Li, C C; Chen, C; Wang, Y; Wang, Y; He, M; Ding, S N; Wei, M W; Tian, H; Kong, X X; Dong, C; Zhou, L; Peng, J F; Wang, Z G; Zhu, F C; Zhu, L G.
  • Jin LR; School of Public Health, Southeast University, Nanjing 210009, China.
  • Li CC; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Chen C; Institute of Acute Infectious Disease Control, Changzhou Municipal Center for Disease Control and Prevention, Changzhou 213000, China.
  • Wang Y; Institute of Acute Infectious Disease Control, Yangzhou Municipal Center for Disease Control and Prevention, Yangzhou 225000, China.
  • Wang Y; Laboratory Department, Yangzhou Municipal Center for Disease Control and Prevention, Yangzhou 225000, China.
  • He M; Laboratory Department, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China.
  • Ding SN; Institute of Acute Infectious Disease Control, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, China.
  • Wei MW; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Tian H; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Kong XX; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Dong C; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Zhou L; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Peng JF; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Wang ZG; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Zhu FC; Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Zhu LG; School of Public Health, Southeast University, Nanjing 210009, China Institute of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
Zhonghua Yu Fang Yi Xue Za Zhi ; 56(12): 1834-1837, 2022 Dec 06.
Article in Chinese | MEDLINE | ID: covidwho-2201077
ABSTRACT
Between August and September, 2021, this study included 605 SARS-CoV-2 natural infection cases and 589 SARS-CoV-2 breakthrough cases from Nanjing and Yangzhou, as well as 690 inactivated COVID-19 vaccine recipients from Changzhou, China. In SARS-CoV-2 natural infection cases, the age range was 19-91 years (median age 66 year), and the medians(Q1,Q3) of IgG titers were 0.19 (0.06-1.31), 3.70 (0.76-69.48), 15.31 (2.59-82.16), 4.41 (0.99-31.74), 2.31 (0.75-13.83), 2.28 (0.68-9.94) and 2.80 (1.00-9.53) at one to seven weeks after SARS-CoV-2 infection, respectively. In SARS-CoV-2 breakthrough cases, the age range was 18-76 years (median age 45 year), and the medians(Q1,Q3)of IgG titers were 1.93 (0.34-26.67), 38.87 (7.90-121.0), 75.09 (11.85-123.70), 21.97 (5.20-95.58), 13.97 (3.47-46.82), 9.56 (2.48-33.38) and 4.38 (1.87-11.00) at one to seven weeks after SARS-CoV-2 infection, respectively. In inactivated COVID-19 vaccine recipients, the age range was 18-87 years (median age 47 years), and the medians(Q1,Q3)of IgG titers were 16.22 (15.84-33.42), 5.35 (2.96-13.23), 3.30 (2.18-6.18), 3.14 (1.16-5.70), 2.77 (1.50-4.52), 2.72 (1.76-4.36), 2.01 (1.27-3.51) and 1.94 (1.35-3.09) at one to eight months after SARS-CoV-2 infection, respectively. The results suggested that IgG antibodies increased gradually within two weeks after SARS-CoV-2 infection, then declined gradually at three to seven weeks in SARS-CoV-2 natural infection cases. In SARS-CoV-2 breakthrough cases, IgG antibodies increased rapidly within two weeks, then declined gradually at three to seven weeks after SARS-CoV-2 infection. Additionally, IgG antibodies decreased rapidly within three months, then decreased gradually and remained at a low level within three months after immunization.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: Chinese Journal: Zhonghua Yu Fang Yi Xue Za Zhi Year: 2022 Document Type: Article Affiliation country: Cma.j.cn112150-20220621-00639

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Language: Chinese Journal: Zhonghua Yu Fang Yi Xue Za Zhi Year: 2022 Document Type: Article Affiliation country: Cma.j.cn112150-20220621-00639